A transcriptional activity assay showed that Mithramycin A significantly decreased SP1 transcriptional activity in all TFE3-fusion RCC cell lines tested (Fig. 3G) and expression of the downstream target BIRC5 was dramatically reduced upon drug treatment (Fig. 3H). The gene discussed is SP1; the disease is renal cell carcinoma.